Apparently the link I posted seems to have a problem. This article is free so I have posted the link below. You just need to click on the button which say access this article for free and it should take you to the correnct page to view the full text. Hope this one works.

Press release:  25th September 2011. Vaxil BioTherapeutics Ltd. a clinical-stage vaccine development company announced today that it has submitted a patent application to the United States Patent Office (USPTO) dealing with a novel use of signal peptides and naturally generated autoantibodies to signal peptides as a tool in the diagnosis and prognosis of various diseases. Read More

Leukemia , (11 November 2011) | doi:10.1038/leu.2011.323  

Variant Philadelphia (Ph) chromosome translocations have been reported in 5%-10% of patients with newly diagnosed chronic myeloid leukemia (CML). Variant translocations may involve one or more chromosomes in addition to 9 and 22, and can be generated by 2 different mechanisms, 1-step and 2-step rearrangements, as revealed by fluorescence in situ hybridization. The prognostic significance of the occurrence of variant translocations has been discussed in previous studies. The European LeukemiaNet recommendations do not provide a “warning” for patients with variant translocations, but there is limited information about their outcome after therapy with tyrosine kinase inhibitors. To identify the role of variant translocations in early chronic phase (CP) CML patients treated with imatinib mesylate, we performed an analysis in a large series of 559 patients enrolled in 3 prospective imatinib trials of the Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA) Working Party on CML. Variant translocations occurred in 30 patients (5%). Our data show that the presence of variant translocations has no impact on the cytogenetic and molecular response or on outcome, regardless of the involvement of different mechanisms, the number of involved chromosomes, or the presence of deletions. Therefore, we suggest that patients with variant translocations do not constitute a “warning” category in the imatinib era.

STIM Study Examines Sustainability of Complete Molecular Response After Stopping Imatinib in CML

Elsevier Global Medical News. 2010 Jan 13, P Wendling

Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial